tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

InhaleRx Begins Manufacturing for Key Cancer Pain Trial

Story Highlights
  • InhaleRx Limited is developing inhaled therapies for pain management and mental health.
  • The company has started manufacturing IRX-211 for a Phase 2 trial, marking a key milestone.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
InhaleRx Begins Manufacturing for Key Cancer Pain Trial

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

InhaleRx Limited ( (AU:IRX) ) has provided an update.

InhaleRx Limited has commenced manufacturing its lead investigational product, IRX-211, for a Phase 2 clinical trial targeting breakthrough cancer pain, marking a significant operational milestone. The manufacturing is being conducted by Ab Initio Pharma, and this step signifies the company’s transition from development to clinical supply readiness, potentially offering a much-needed solution for patients and strengthening its market position.

More about InhaleRx Limited

InhaleRx Limited is an Australian clinical-stage drug development company focused on creating rapid onset inhaled therapies to address unmet medical needs in the pain management and mental health sectors. The company is working on obtaining U.S. FDA approval for its products using efficient regulatory pathways, with a significant economic opportunity anticipated for shareholders.

Average Trading Volume: 317,166

Technical Sentiment Signal: Buy

Current Market Cap: A$7.9M

For an in-depth examination of IRX stock, go to TipRanks’ Overview page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1